Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Background: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potentially represent a treatment for fatty liver disease. The mechanisms behind these effects are still not fully elucidated. The aim of the study was to investigate whether treatment with liraglutide is associated with favourable metabolic changes in cases of both CV disease and fatty liver disease. Methods: In a prespecified post-hoc analysis of a double-blind, placebo-controlled trial in 62 individuals with type 2 diabetes (GLP-1 RA liraglutide or glimepiride, both in combination with metformin), we evaluated the changes in plasma molecular lipids and polar metabolites after 18 weeks of treatment. The lipids and polar metabolites were measured by using ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UHPLC-QTOFMS). Results: In total, 340 lipids and other metabolites were identified, covering 14 lipid classes, bile acids, free fatty acids, amino acids and other polar metabolites. We observed more significant changes in the metabolome following liraglutide treatment compared to with glimepiride, particularly as regards decreased levels of cholesterol esters hexocyl-ceramides, lysophosphatidylcholines, sphingolipids and phosphatidylcholines with alkyl ether structure. In the liraglutide-treated group, lipids were reduced by approximately 15% from baseline, compared to a 10% decrease in the glimepiride group. At the pathway level, the liraglutide treatment was associated with lipid, bile acid as well as glucose metabolism, while glimepiride treatment was associated with tryptophan metabolism, carbohydrate metabolism, and glycerophospholipid metabolism. Conclusions: Compared with glimepiride, liraglutide treatment led to greater changes in the circulating metabolome, particularly regarding lipid metabolism involving sphingolipids, including ceramides. Our findings are hypothesis-generating and shed light on the underlying biological mechanisms of the CV benefits observed with GLP-1 RAs in outcome studies. Further studies investigating the role of GLP-1 RAs on ceramides and CV disease including fatty liver disease are warranted. Trial registration: NCT01425580
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Heatmap depicting log2 transformed levels of metabolites at baseline and after treatment [glimepiride + metformin (G) vs. liraglutide + metformin (L)]. Groups were further divided into subjects with myocardial infarction (MI) or without MI (C, control)](https://figures.cochat.ai/paper-figures/f80c87c143c94a1ba75742434dd8b39d/pharmacometabolomic-profiles-in-type-2-diabetic-subjects-treated-with-figure-1.jpg)
![Fig. 2 A Heatmap demonstrating differences in lipids, at baseline, between individuals with (n = 21) or without myocardial infarction (MI) (n = 41). B Selected examples of lipids, i.e., ceramide [Cer(d18:1/24:1)], triacylglycerol [TG(56:3)] and phosphatidylethanolamine [PE(35:5)], showing significant differences at baseline between groups with or without MI, with adjusted p values marked to the boxplots](https://figures.cochat.ai/paper-figures/f68170fbf24e470ab39636e61fadd6cc/pharmacometabolomic-profiles-in-type-2-diabetic-subjects-treated-with-figure-2.jpg)
![Fig. 3 A Heatmap of fold changes between treated groups [glimepiride (G) vs. liraglutide (L)]. B Selected examples of lipids, i.e., phosphatidylcholine [PC(36:4)], phosphatidylethanolamines [PE(18:1/8:2)], lysophosphatidylcoline [LPC(18:2)] and triacylglycerol [TG(18:0/18:1/20:4)], showing significant difference between treated groups [glimepiride (G) vs. liraglutide (L)], with adjusted p values marked to the boxplots](https://figures.cochat.ai/paper-figures/2f6fea6e353e4354933c0261262de0f2/pharmacometabolomic-profiles-in-type-2-diabetic-subjects-treated-with-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, Jendle et al.134 showed that 18 weeks of treatment with liraglutide compared with glimepiride significantly reduced a more significant number of lipid species, including ceramides, PCs, phosphatidylinositol, cholesterol esters, and sphingomyelins.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“In the LEADER (Liraglutide Effect and Action in Diabetes) trial [6] the time-to-event analysis for the composite endpoint, i.”
BackgroundChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803 · cited 1×
“A third of people with NAFLD are likely to progress to non-alcoholic steatohepatitis (NASH), defined as the presence of hepatic steatosis and lobular inflammation with hepatocyte injury with or without fibrosis [38].”
BackgroundMetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis
Chong, J., Soufan, O., Li, C., Caraus, I., Li, S., Bourque, G., Wishart, D. S., & Xia, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky310 · Cited by 3,629 · cited 1×
“0 web platform, using the Functional Analysis (MS Peaks) module and using both the Mummichog algorithm as well as the GSEA algorithm [18].”
MethodByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042 · cited 1×
“NAFLD is considered as being related to metabolic syndrome, and is highly associated with peripheral and hepatic insulin resistance, obesity, T2D, dyslipidemia and CV disease [37].”
BackgroundArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · cited 1×
“It was also recently shown that ameliorative effects occur in non-alcoholic steatohepatitis (NASH) in patients treated with liraglutide [7].”
BackgroundMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“Several clinical studies with the treatment of GLP-1 RAs shown improved lipid metabolism and amelioration of cardiometabolic risk factors [21].”
BackgroundObesity Phenotypes, Diabetes, and Cardiovascular Diseases
Piché, M.-E., Tchernof, A., & Després, J.-P. (2020) · Circulation Research · doi:10.1161/circresaha.120.316101 · Cited by 1,986 · cited 3×
“This supports the hypothesis that these disturbances are related to lipotoxic environment due to dysfunctional adipose tissues and therefore cardiometabolic consequences [2, 4].”
BackgroundMethodGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“Beside the reduction in weight and glucose levels of liraglutide treatment, there are several indirect actions reported regarding heart function and the vessel evoked by activation of GLP-1 receptors (GLP-1 R) [8, 9].”
BackgroundWong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414 · cited 2×
“The arachidonic acid (AA) pathway, on the other hand, has been shown to play a key role in cardiovascular biology, particularly in relation to inflammatory processes [44, 45].”
BackgroundStefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837 · cited 1×
“This supports the hypothesis that these disturbances are related to lipotoxic environment due to dysfunctional adipose tissues and therefore cardiometabolic consequences [2, 4].”
BackgroundNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745 · cited 2×
“Sample preparation Plasma samples, collected [1] at baseline and [2] after 18 weeks of treatment with liraglutide + metformin or glimepiride + metformin, were immediately centrifuged and aliquotted into Eppendorf tubes and stored at − 80 °C until analysis.”
BackgroundMethodMetformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733 · cited 1×
“One of the explanations, for this finding, may be due to the co-treatment of metformin which as it is known to reduce serum bile acids and increase the intestinal bile acid pool, probably by decreasing ileal bile acid reuptake [43].”
BackgroundGall, W. E., Beebe, K., Lawton, K. A., Adam, K.-P., Mitchell, M. W., Nakhle, P. J., Ryals, J. A., Milburn, M. V., Nannipieri, M., Camastra, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010883 · Cited by 698
Laaksonen, R., Ekroos, K., Sysi-Aho, M., Hilvo, M., Vihervaara, T., Kauhanen, D., Suoniemi, M., Hurme, R., März, W., Scharnagl, H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw148 · Cited by 674 · cited 1×
“It was also recently found that accumulation of ceramides associates with de novo lipogenesis and insulin resistance leading to low-grade inflammation [33], which, in turn, is suggested to increase the risk of T2D and CV disease [34].”
BackgroundLuukkonen, P. K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., Hyötyläinen, T., & Yki-Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.002 · Cited by 461 · cited 9×
“As increased accumulation of ceramides highly associates with CV disease and NAFLD, further studies are warranted investigating the role of GLP-1 RAs in these conditions.”
BackgroundInfluentialSelf-citationArachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases
Sonnweber, T., Pizzini, A., Nairz, M., Weiss, G., & Tancevski, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113285 · Cited by 440 · cited 1×
“The arachidonic acid (AA) pathway, on the other hand, has been shown to play a key role in cardiovascular biology, particularly in relation to inflammatory processes [44, 45].”
BackgroundLotta, L. A., Sharp, S. J., Burgess, S., Perry, J. R. B., Stewart, I. D., Willems, S. M., Luan, J., Ardanaz, E., Arriola, L., Balkau, B., et al. (2016) · JAMA · doi:10.1001/jama.2016.14568 · Cited by 394
Plasma Sphingomyelin Level as a Risk Factor for Coronary Artery Disease
Jiang, X.-C., Paultre, F., Pearson, T. A., Reed, R. G., Francis, C. K., Lin, M., Berglund, L., & Tall, A. R. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.12.2614 · Cited by 386 · cited 1×
“Ceramides show evidence of being key mediators of lipotoxicity [30], and strong biomarkers of atherosclerosis [31].”
BackgroundThe failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense
Horton, J. L., Davidson, M. T., Kurishima, C., Vega, R. B., Powers, J. C., Matsuura, T. R., Petucci, C., Lewandowski, E. D., Crawford, P. A., Muoio, D. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124079 · Cited by 364
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347 · cited 1×
“Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lead to multiple metabolic changes, whereas reduction in glucose levels and body weight are well-established indications for the treatment of T2D and or obesity [5].”
BackgroundJendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Self-citationMetabolic Messengers: ceramides
Summers, S. A., Chaurasia, B., & Holland, W. L. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0134-8 · Cited by 299 · cited 1×
“It was also recently found that accumulation of ceramides associates with de novo lipogenesis and insulin resistance leading to low-grade inflammation [33], which, in turn, is suggested to increase the risk of T2D and CV disease [34].”
BackgroundGenetic Determinants of Circulating Sphingolipid Concentrations in European Populations
Hicks, A. A., Pramstaller, P. P., Johansson, Å., Vitart, V., Rudan, I., Ugocsai, P., Aulchenko, Y., Franklin, C. S., Liebisch, G., Erdmann, J., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000672 · Cited by 214
Role of sphingolipids in senescence: implication in aging and age-related diseases
Trayssac, M., Hannun, Y. A., & Obeid, L. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97949 · Cited by 202 · cited 1×
“Ceramides show evidence of being key mediators of lipotoxicity [30], and strong biomarkers of atherosclerosis [31].”
BackgroundThe Biosynthesis of Enzymatically Oxidized Lipids
Hajeyah, A. A., Griffiths, W. J., Wang, Y., Finch, A. J., & O’Donnell, V. B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.591819 · Cited by 180 · cited 2×
“Enzymatic lipid oxidation is facilitated by a network of proteins that use polyunsaturated fatty acids (PUFA) such as arachidonic acid, or sterols as substrates, and specifically, cytochrome P450 (CYP) [46] account for many enzymes in both pathways, catalyzing the formation of both oxysterols as well as oxygenated PUF…”
BackgroundRole of diet and fuel overabundance in the development and progression of heart failure
Chess, D. J., & Stanley, W. C. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn074 · Cited by 140 · cited 1×
“, heart failure or coronary artery disease [2, 3].”
BackgroundOhki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139 · cited 10×
“, ceramides, liraglutide treatment may be considered as one potential drug with activity against NAFLD [40, 41].”
BackgroundInfluentialMatikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129 · cited 16×
“The strengths of this study include its double-blind, placebo-controlled nature, randomization and that we used three comprehensive parallel methods based on high-resolution mass spectrometry, to investigate metabolic changes in subjects with new compared to older antidiabetic drugs for the treatment of T2D.”
BackgroundResultInfluentialAkawi, N., Checa, A., Antonopoulos, A. S., Akoumianakis, I., Daskalaki, E., Kotanidis, C. P., Kondo, H., Lee, K., Yesilyurt, D., Badi, I., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.314 · Cited by 111 · cited 9×
“As increased accumulation of ceramides highly associates with CV disease and NAFLD, further studies are warranted investigating the role of GLP-1 RAs in these conditions.”
BackgroundInfluentialSalihović, S., Dickens, A. M., Schoultz, I., Fart, F., Sinisalu, L., Lindeman, T., Halfvarson, J., Orešič, M., & Hyötyläinen, T. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-02263-6 · Cited by 91
Self-citationNyström, T. (2008) · Hormone and Metabolic Research · doi:10.1055/s-0028-1082326 · Cited by 76 · cited 1×
“Beside the reduction in weight and glucose levels of liraglutide treatment, there are several indirect actions reported regarding heart function and the vessel evoked by activation of GLP-1 receptors (GLP-1 R) [8, 9].”
BackgroundSelf-citationFarr, S., Taher, J., & Adeli, K. (2014) · Cardiovascular & Hematological Disorders-Drug Targets · doi:10.2174/1871529x14666140505125300 · Cited by 61 · cited 1×
“This may be due to an impact of GLP-1 on lipid absorption in the intestine, and its overall role in regulation of lipoprotein metabolism [27, 28].”
BackgroundPeradze, N., Farr, O. M., Perakakis, N., Lázaro, I., Sala-Vila, A., & Mantzoros, C. S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0945-7 · Cited by 61
McGlinchey, A., Sinioja, T., Lamichhane, S., Sen, P., Bodin, J., Siljander, H., Dickens, A. M., Geng, D., Carlsson, C., Duberg, D., et al. (2020) · Environment International · doi:10.1016/j.envint.2020.105935 · Cited by 61
Self-citationAngulo, P. (2011) · Hepatology · doi:10.1002/hep.24403 · Cited by 58
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., Nieuwdorp, M., Groen, A. K., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12748 · Cited by 56 · cited 1×
“Whilst it has been suggested that GLP‐1‐based therapies may have a role in biliary physiology, previous studies have not reported any major changes in fasting bile acid levels after treatment with liraglutide, with the secondary bile acids acid, deoxycholic acid (DCA), being an exception [42].”
BackgroundBretón‐Romero, R., Weisbrod, R. M., Feng, B., Holbrook, M., Ko, D., Stathos, M. M., Zhang, J., Fetterman, J. L., & Hamburg, N. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009379 · Cited by 54 · cited 1×
“We have no clinical data on insulin sensitivity; since liraglutide may play a role in reducing insulin resistance and endothelial dysfunction [47] the metabolic changes between groups may be explained by changes in insulin sensitivity evoked by liraglutide.”
BackgroundLuo, Y., Yang, P., Li, Z., Luo, Y., Shen, J., Li, R., Zheng, H., Liang, Y., & Xia, N. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s224688 · Cited by 44 · cited 10×
“, ceramides, liraglutide treatment may be considered as one potential drug with activity against NAFLD [40, 41].”
BackgroundInfluentialRuuth, M. K., Lahelma, M., Luukkonen, P. K., Lorey, M. B., Qadri, S. U., Sädevirta, S., Hyötyläinen, T., Kovanen, P. T., Hodson, L., Yki‐Järvinen, H., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315766 · Cited by 42 · cited 1×
“Also, a high fat diet was found to have a similar, but stronger impact [48].”
BackgroundSelf-citationGlucosylceramide synthase deficiency in the heart compromises β1-adrenergic receptor trafficking
Andersson, L. K., Cinato, M., Mardani, I., Miljanovic, A., Arif, M., Koh, A., Lindbom, M., Laudette, M., Bollano, E., Ömerovic, E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab412 · Cited by 38 · cited 2×
“Analysis of highly-polar metabolites was done as described in [17].”
BackgroundSelf-citationThe effects of liraglutide in mice with diet-induced obesity studied by metabolomics
Bugáňová, M., Pelantová, H., Holubová, M., Šedivá, B., Maletínská, L., Železná, B., Kuneš, J., Kačer, P., Kuzma, M., & Haluzík, M. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0478 · Cited by 36 · cited 1×
“Metabolomic studies in mice using nuclear magnetic resonance (NMR) spectroscopy, which is more restricted in terms of metabolomics coverage due to lower sensitivity than mass spectrometry, found that treatment with liraglutide alters β-oxidation in fatty acids also affects the microbiome, independently of other metabo…”
BackgroundZobel, E. H., Wretlind, A., Ripa, R. S., Rotbain Curovic, V., von Scholten, B. J., Suvitaival, T., Hansen, T. W., Kjær, A., Legido-Quigley, C., & Rossing, P. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002395 · Cited by 31 · cited 1×
“Multiple sphingolipids, including glycoceramides, a class of bioactive sphingolipids, were found to be decreased in subjects treated with liraglutide [29].”
BackgroundNyström, T., Santos‐Pardo, I., Hedberg, F., Wardell, J., Witt, N., Cao, Y., Bojö, L., Nilsson, B., & JENDLE, J. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00325 · Cited by 27
Self-citationGLP1, an Important Regulator of Intestinal Lipid Metabolism
Dallinga‐Thie, G. M., & Nieuwdorp, M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305479 · Cited by 17 · cited 1×
“This may be due to an impact of GLP-1 on lipid absorption in the intestine, and its overall role in regulation of lipoprotein metabolism [27, 28].”
BackgroundNyström, T., Santos‐Pardo, I., Fang, X. L., Cao, Y., Hedberg, F., & JENDLE, J. H. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.58 · Cited by 17
Self-citationJENDLE, J. H., Fang, X. L., Cao, Y., Bojö, L., Nilsson, B., Hedberg, F., Santos‐Pardo, I., & Nyström, T. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.02.003 · Cited by 8
Self-citation
Cited by
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Angelidi, A. M., Kokkinos, A. D., Sanoudou, D., Connelly, M. A., Alexandrou, A. P., Mingrone, G., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155346 · Cited by 62
Gao, J., Yang, T., Song, B., Ma, X., Ma, Y., Lin, X., & Wang, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115395 · Cited by 65
Piccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 58
“Conversely, other findings showed minor or no significant impact on the levels of free fatty acids and glycerol after liraglutide treatment [84,85].”
BackgroundLiraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure
Sforza, A., Vigorelli, V., Rurali, E., Perrucci, G. L., Gambini, E., Arici, M., Metallo, A., Rinaldi, R., Fiorina, P., Barbuti, A., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01486-9 · Cited by 38
“ceramide) [24] and LDL metabolism, this latter by reduction of plasma PCSK9 level [25].”
Background
Metadata
- Authors
- Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T.
- Affiliations
- Örebro University (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Jendle, J.
- Venue
- Cardiovascular Diabetology
- Published
- 2021-12
- Volume
- 20
- Issue
- 1
- Pages
- 237-237
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC8684205
- OpenAlex
- W4200606167
- Cited by
- 27
- References
- 48
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 7 · 2023: 10 · 2022: 4
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 16 d)
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novo Nordisk
- Örebro University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, glimepiride, type 2 diabetes, pharmacometabolomics, GLP-1 receptor agonists, plasma lipid metabolism, sphingolipids, ceramide, lysophosphatidylcholine, bile acids, hepatic steatosis, cardiovascular disease, metformin, tryptophan metabolism, glycerophospholipid metabolism, glucose metabolism
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Lipidomics, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Chromatography, High Pressure Liquid, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents, Lipids, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Time Factors, Biomarkers, Treatment Outcome, Spectrometry, Mass, Electrospray Ionization, Incretins, Metabolomics, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.